TherapeuticsMD Inc
TXMD
查看详细走势图
2.290USD
+0.100+4.57%
收盘 02/06, 16:00（美东）报价延迟15分钟
26.50M总市值
87.50市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
+4.57%
5天
+6.02%
1月
+12.25%
6月
+107.24%
今年开始到现在
+40.49%
1年
+126.73%
查看详细走势图
TradingKey TherapeuticsMD Inc股票评分
单位: USD 更新时间: 2026-02-05操作建议
TherapeuticsMD Inc当前公司基本面数据相对非常健康，最新ESG披露属于行业领先水平。增长潜力很大。当前估值合理，在药品行业排名120/159位。机构持股占比非常高，中期看，股价处于上升通道。近一个月，市场表现较强，技术面和基本面综合得分较高，较强的走势得到基本面和技术面的印证。目前股价在压力位和支撑位之间，可以做区间波段操作。
TherapeuticsMD Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
看空
TherapeuticsMD Inc亮点
亮点风险
TherapeuticsMD, Inc. is a pharmaceutical royalty company, which primarily collects royalties from its licensees. It receives royalties on products licensed to pharmaceutical organizations that possess commercial capabilities in the relevant territories. It granted a license to commercialize IMVEXXY, BIJUVA, and prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands and assigned its exclusive license to commercialize ANNOVERA to Mayne Pharma. IMVEXXY (estradiol vaginal inserts) pharmaceutical product is for the treatment of moderate-to-severe dyspareunia. BIJUVA pharmaceutical product is a Food and Drug Administration (FDA)-approved bioidentical hormone therapy combination of estradiol and progesterone in a single, oral capsule for the treatment of moderate-to-severe vasomotor symptoms due to menopause in women with a uterus. ANNOVERA pharmaceutical product is a one-year ring-shaped contraceptive vaginal system (CVS).
业绩增长期
公司处于发展阶段，最新年度总收入1.76M美元
估值高估
公司最新PE估值83.68，处于3年历史高位
机构减仓
最新机构持股3.33M股，环比减少0.64%
先锋集团持仓
明星投资者先锋集团持仓，最新持仓市值397.06K
分析师目标
根据
0
位分析师
--
评级
--
目标均价
--
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
TherapeuticsMD Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
TherapeuticsMD Inc简介
TherapeuticsMD, Inc. is a pharmaceutical royalty company, which primarily collects royalties from its licensees. It receives royalties on products licensed to pharmaceutical organizations that possess commercial capabilities in the relevant territories. It granted a license to commercialize IMVEXXY, BIJUVA, and prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands and assigned its exclusive license to commercialize ANNOVERA to Mayne Pharma. IMVEXXY (estradiol vaginal inserts) pharmaceutical product is for the treatment of moderate-to-severe dyspareunia. BIJUVA pharmaceutical product is a Food and Drug Administration (FDA)-approved bioidentical hormone therapy combination of estradiol and progesterone in a single, oral capsule for the treatment of moderate-to-severe vasomotor symptoms due to menopause in women with a uterus. ANNOVERA pharmaceutical product is a one-year ring-shaped contraceptive vaginal system (CVS).
公司代码TXMD
公司TherapeuticsMD Inc
CEOWalker (Marlan D)
网址https://www.therapeuticsmd.com/
相关品种
